



Pharma Finance 2007

ROMA - ITALY - MAY 10-11

5TH ANNUAL PARTNERING CONFERENCE

Market Data (AS OF MAY 1, 2007)



Symbol	CBLI
Exchange	NASDAQ
Current Price	\$9.45
Shares Outstanding	11.9M
Market Capital	\$112.4M
52wk RANGE	\$4.17-\$13.99
Average Volume	235,792
YTD % Change	12.31%

COMPANY FACT SHEET



Cleveland BioLabs, Inc.
 11000 Cedar Avenue
 Suite 290
 Cleveland, OH 44106-3052
 (216) 229-2251

www.cbilabs.com



Michael Fonstein, PH.D.
 President and CEO

FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

Net Revenue:	1.71M	Earnings per Share:	(0.84)
Net Income:	(7.44M)	Weighted Average:	8.9M

CONFERENCE OBJECTIVES

Investment and Partnering Opportunities

RECENT DEVELOPMENTS

April 9, 2007

Cleveland BioLabs Protectan CBLB502 Demonstrates Strong Survival Benefits as Mitigator Against Radiation-Induced Damage in Study

April 5, 2007

Cleveland BioLabs Phase II Hormone-Refractory Prostate Cancer Trial Advances to Next Phase

March 20, 2007

Cleveland BioLabs Receives Developmental Grant from Department of Defense for Protectan CBLB502

PRODUCT AND PRODUCT CANDIDATE PIPELINE

Protectan CBLB502

Modified protein of a bacteria that temporarily suppresses apoptosis, and which therefore has a broad spectrum of potential applications including protection from exposure to radiation (whether as a result of military or terrorist action or nuclear accident), as well as medical applications such as reducing cancer treatment side effects, or prevention of acute organ failure. Demonstrated survival benefits as radiation protector in animal models and being submitted for US Dept. of Defense RFP in 2007.

Curaxin CBLC102

Safe, oral, small molecule that kills tumor cells by simultaneously targeting two regulators of apoptosis. Demonstrates efficacy in vitro, in animal models, and in live tumors removed from human patients. Successfully progressed into second cohort of Phase II trial in androgen-independent (hormone refractory) prostate cancer. Additional Phase II trials in RCC and Multiple Myeloma to begin later this year.

Company Description

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.